Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment

Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment

Abstract Introduction Omaveloxolone, the only approved medication for Friedreich ataxia (FRDA), is an NRF2 activator available since July 2023. We examined safety monitoring of omaveloxolone administration over the first 12 months of administration. Methods We recorded baseline and follow-up serum t...

Full description

Saved in:
Bibliographic Details
Main Authors: Katherine Gunther, Victoria Profeta, Medina Keita, Courtney Park, McKenzie Wells, Sonal Sharma, Kimberly Schadt, David R. Lynch
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Neurology and Therapy
Subjects:
Brain natriuretic peptide
Mitochondria transaminase
Movement disorder
Omaveloxolone
Online Access:https://doi.org/10.1007/s40120-025-00749-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-025-00749-3

Similar Items